BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 204 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q2 2019. The put-call ratio across all filers is 0.22 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $17,739,000 | -3.3% | 213,362 | -3.3% | 0.01% | 0.0% |
Q2 2022 | $18,348,000 | -20.3% | 220,695 | +12.3% | 0.01% | 0.0% |
Q1 2022 | $23,016,000 | +9.6% | 196,518 | -1.5% | 0.01% | +16.7% |
Q4 2021 | $21,001,000 | -29.6% | 199,459 | -9.8% | 0.01% | -33.3% |
Q3 2021 | $29,843,000 | +33.9% | 221,056 | -3.7% | 0.01% | +28.6% |
Q2 2021 | $22,281,000 | +45.5% | 229,516 | +2.4% | 0.01% | +40.0% |
Q1 2021 | $15,318,000 | -51.9% | 224,109 | -39.7% | 0.01% | -54.5% |
Q4 2020 | $31,835,000 | +77.7% | 371,433 | +34.8% | 0.01% | +57.1% |
Q3 2020 | $17,919,000 | -18.6% | 275,634 | -8.5% | 0.01% | -22.2% |
Q2 2020 | $22,016,000 | +251.1% | 301,130 | +63.4% | 0.01% | +200.0% |
Q1 2020 | $6,270,000 | -75.2% | 184,254 | -60.4% | 0.00% | -70.0% |
Q4 2019 | $25,304,000 | -30.0% | 464,807 | -46.4% | 0.01% | -33.3% |
Q3 2019 | $36,174,000 | -6.8% | 867,072 | -2.1% | 0.02% | 0.0% |
Q2 2019 | $38,799,000 | – | 886,025 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Knoll Capital Management, LLC | 896,844 | $123,594,000 | 67.92% |
RP Management, LLC | 1,111,111 | $153,122,000 | 64.09% |
ORACLE INVESTMENT MANAGEMENT INC | 2,075,402 | $286,011,000 | 40.64% |
ARS Investment Partners, LLC | 463,392 | $63,860,000 | 5.86% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 300,373 | $41,394,000 | 4.76% |
SILVERARC CAPITAL MANAGEMENT, LLC | 80,348 | $11,073,000 | 4.49% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 139,900 | $19,282,000 | 4.30% |
Avidity Partners Management LP | 1,140,000 | $157,103,000 | 3.33% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 200,000 | $27,562,000 | 3.17% |
Eventide Asset Management | 1,635,000 | $225,319,000 | 2.88% |